



Increlex (mecasermin) solution for subcutaneous injection	
Indication	Increlex is used for the long-term treatment of patients aged 2 to 18 years who are of short stature due to a condition known as 'severe primary insulin-like growth factor-1 deficiency'.
Reason for shortage	<p>In April 2013, problems at the manufacturing site in the United States led to an interruption in the manufacture of the active substance. This led to a shortage in the supply of Increlex in August 2013. The problems were linked to equipment failures at the site which are currently being addressed by the company.</p> <p>Information issued previously by the EMA on the supply situation for Increlex can be found here.</p>
Member States affected¹	All European Union (EU) Member States where Increlex was available.
Information to healthcare professionals	<ul style="list-style-type: none">• A letter from the marketing authorisation holder was sent out to healthcare professionals in April 2013.• No new patients should be started on Increlex until normal supplies are re-established.• There are no alternative treatment options for severe primary insulin-like growth factor-1 deficiency and patient's treatment will have to be interrupted. When stopping treatment hypoglycaemia could re-occur in patients who experienced hypoglycaemic episodes before starting treatment with Increlex. Patients should therefore be monitored as appropriate.• The marketing authorisation holder has established an advisory board of external experts to answer any queries from healthcare professionals. Contact details are included in the letter that was sent to healthcare professionals or are available from the company.• Additional advice may be available from the national competent authority.
Information to patients	<ul style="list-style-type: none">• Increlex is currently unavailable and treatment will have to be interrupted. During this period, patients may have to be regularly reviewed by their doctor.• There are no alternative treatment options for severe

¹ This information may change. For accurate information about the status of a medicine shortage in a particular member state the national competent authority should be contacted.



Increlex (mecasermin) solution for subcutaneous injection

	<p>primary insulin-like growth factor-1 deficiency.</p> <ul style="list-style-type: none">• Patients who have any questions should speak to their doctor or pharmacist.• Additional advice may be available from the national competent authority.• Patients may also contact Eurordis, an organisation representing people with rare disease in Europe.
Status	Ongoing
Date of publication	4 November 2013